Assess your compound ADME and safety profile

Human liver organoids model drug induced liver injury (DILI) and drug metabolism

Can you predict your compound hepatotoxicity?

Discover how HUB Organoids^™ help derisk preclinical drug development programs

With one in three market withdrawals due to hepatotoxicity issues, advanced preclinical models that can effectively predict DILI are sorely needed.

HUB Organoids are a clinically-relevant, patient-derived system for the preclinical investigation of drug safety and toxicity, that can help you reduce the chance of failure at a later stage in drug discovery and development.

HUB Organoids benefits include:

• More accurate predictivity of hepatotoxic effects compared to traditional in vitro or in vivo models
• Physiological relevance thanks to specific culturing conditions allowing their development from liver stem cells which differentiate into mature hepatocytes
• Disease-specificity thanks to being derived directly from patient liver tissue
• Robust expansion capability for large scale screens